Novo Nordisk halts two cardiovascular inflammation trials

Novo Nordisk discontinued two trials testing an anti-inflammatory drug for cardiovascular benefit, marking a setback for the inflammation hypothesis in cardiovascular disease. The company has not disclosed reasons, and the impact on its pipeline and the broader field remains uncertain.